{"id":49422,"date":"2024-03-14T20:01:28","date_gmt":"2024-03-14T20:01:28","guid":{"rendered":"https:\/\/www.arisglobal.com\/?p=49422"},"modified":"2024-09-05T08:20:51","modified_gmt":"2024-09-05T08:20:51","slug":"why-cloud-is-the-only-modern-safety-option","status":"publish","type":"post","link":"https:\/\/www.arisglobal.com\/blogs\/why-cloud-is-the-only-modern-safety-option\/","title":{"rendered":"Why cloud is the only modern option for efficient, high-volume Safety data processing"},"content":{"rendered":"

At Breakthrough 2024 this month, Sam Wallis, Head of ICSR Case Processing within the Worldwide Patient Safety Operations at Bristol Myers Squibb, will join a panel discussion on the reality of transitioning Safety\/Regulatory systems to the cloud. Here, he provides a glimpse into BMS\u2019s own journey, which he\u2019ll share candidly during the Day 1 debate.<\/span><\/h3>\n

\"Samuel<\/p>\n

By the time I sit down to this much-anticipated panel discussion on the journey to the cloud, and specifically LifeSphere MultiVigilance, it will be two years since Bristol Myers Squibb (BMS) made the transition with our worldwide Safety database. I\u2019m looking forward to sharing our expectations and real experiences, and what we\u2019ve learnt along the way \u2013 not least the importance of a trusted partnership with ArisGlobal in ensuring the project\u2019s continued success. <\/span><\/p>\n

With LifeSphere MultiVigilance, we expect to process some 550,000 data points\/receipt items this year. I\u2019m keen to share what we\u2019ve achieved, and how we are striking that all-important balance between exquisite individual case safety reports that users can trust \u2013 in support of benefit\/risk evaluation and the development of assets – while supporting the highly effective and cost-efficient processing of those ICSRs, end to end, through strategic use of automation.<\/p>\n

 <\/p>\n

Effective Safety data processing drives everything else downstream<\/strong><\/h3>\n

Case management – high-quality ICSR generation – is central to any pharmacovigilance and drug safety environment, driving everything else downstream. Ultimately, the integrity and credibility of our Safety database, and efficient associated processes, are paramount to ensure that BMS\u2019s investment in drug development and our post-marketing safety strategy is absolutely focused on bringing medicines through the pipeline and to commercialization, so that we can benefit more patients faster. <\/span><\/p>\n

Until two years ago, our Safety database was managed entirely on premise. In 2022, we faced trying to integrate Celgene\u2019s PV activities with BMS\u2019s, following the company\u2019s acquisition. This was a very large-scale undertaking. Moving from two \u2018heritage\u2019 databases to a multi-tenant cloud environment with LifeSphere MultiVigilance offered a good opportunity to tackle that integration in a sustainable and scalable way via a futureproof platform. (I believe most on-premise Safety databases will be phased out in due course; the cloud is becoming the obvious target for managing these vast data sets.)<\/p>\n

Our experiences of moving to LifeSphere MultiVigilance, working in very close partnership with ArisGlobal, have been interesting and I\u2019ll be very transparent about all of this during the Breakthrough2024 panel discussion. That\u2019s because I know others will benefit a lot from hearing about what works well, where the challenges lie, and how to maximize the advantages of a cloud-based global Safety database on the LifeSphere MultiVigilance platform through close collaboration with ArisGlobal.<\/p>\n

I\u2019ll be just as interested to hear the first-hand experiences of our peers at this interactive session, which I am confident will be well attended – as moving to the cloud is something most companies will have on their roadmaps now, if not their immediate agenda.<\/p>\n

I hope you\u2019ll join us for what promises to be a lively and thought-provoking session.<\/p>\n